Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: Need for primary prophylaxis

Gut

Volumn 53, Issue 9, 2004, Pages 1363-1365

  Esteve, M ^a,b   Saro, C ^c   Gonzalez Huix F ^d   Suarez, F ^e   Forne M ^b   Viver, J M ^b  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b HOSPITAL MÚTUA DE TERRASSA   (Spain)

^c HOSPITAL DE CABUEÑES   (Spain)

^d HOSPITAL JOSEP TRUETA   (Spain)

^e HOSPITAL JUAN CANALEJO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; CIPROFLOXACIN; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B VACCINE; HEPATITIS C ANTIBODY; INFLIXIMAB; LAMIVUDINE; MESALAZINE; METRONIDAZOLE; PREDNISONE; VIRUS RNA;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLADDER FISTULA; BLOOD ANALYSIS; CASE REPORT; CHRONIC HEPATITIS; CLINICAL FEATURE; COLON RESECTION; CROHN DISEASE; DISEASE MARKER; DRUG WITHDRAWAL; ENTERIC FEEDING; HEPATITIS B; HORMONE DEPENDENCE; HUMAN; HUMAN TISSUE; ILEUM RESECTION; INTESTINE RESECTION; LIVER BIOPSY; LIVER FUNCTION; LIVER FUNCTION TEST; MALE; PRIORITY JOURNAL; SEPSIS; VIRUS REPLICATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; CROHN DISEASE; FATAL OUTCOME; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; TUMOR NECROSIS FACTOR-ALPHA; VIRUS ACTIVATION;

EID: 4344614501     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2004.040675     Document Type: Article

References (17)

1. Schreiber S, Campieri M, Colombel JF, et al. Use of anti-tumour necrosis factor agents in inflammatory bowel disease. European guidelines for 2001-2003. Int J Colorectal Dis 2001;16:1-13.
2. Biancone L, Pavia M, Del Vecchio Blanco G, et al. Hepatitis B and C virus infection in Crohn's disease. Inflamm Bowel Dis 2001;7:287-94.
3. Biancone L, Del Vecchio Blanco G, Pallone F, et al. Immunomodulatory drugs in Crohn's disease patients with hepatitis B or C virus infection. Gastroenterology 2002;122:593.
4. Holtmann MH, Galle PR, Neurath MF. Treatment of patients with Crohn's disease and concomitant chronic hepatitis C with a chimeric monoclonal antibody to TNF. Am J Gastroenterol 2003;98:504-5.
5. Campbell S, Ghosh S. Infliximab therapy for Crohn's disease in the presence of chronic hepatitis C infection. Eur J Gastroenterol Hepatol 2001;13:191-2.
6. Ostuni P, Botsios C, Punzi L, et al. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis 2003;62:686-7.
7. Michel M, Duvoux C, Hezode C, et al. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset Still's disease. J Rheumatol 2003;30:1624-5.
8. Oniankitan O, Duvoux C, Challine D, et al. Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C. J Rheumatol 2004;31:107-9.
9. Perrillo RP. Acute flares in chronic hepatitis B: The natural and unnnatural history of an immunologically mediated liver disease. Gastroenterology 2001;120:1009-22.
10. Liaw Y-F. Hepatitis flares and hepatitis B e antigen seroconversion: Implication in anti-hepatitis B virus therapy. J Gastroenterol Hepatol 2003;18:246-52.
11. Rossi G. Prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HBsAg carriers with hemato-oncological neoplasias with chemotherapy. Leuk Lymphoma 2003;44:759-66.
12. Lee WC, Wu MJ, Cheng CH, et al. Lamivudine is effective for the treatment of reactivation of hepatitis B virus and fulminant hepatic failure in renal transplant recipients. Am J Kidney Dis 2001;38:1074-81.
13. Liu CJ, Lai MY, Lee PH, et al. Lamivudine treatment for hepatitis B reactivation in HBsAg carriers after organ transplantation: a 4-year experience. J Gastroenterol Hepatol 2001;16:1001-8.
14. Lau GK, He ML, Fong DY, et al. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology 2002;36:702-9.
15. Conjeevaram HS, Lok AS. Management of chronic hepatitis B. J Hepatol 2003;38(suppl 1):S90-103.
16. Tillmann HL, Wedemeyer H, Manns MP. Treatment of hepatitis B in special patient groups: hemodialysis, heart and renal transplant, fulminant hepatitis, hepatitis B reactivation. J Hepatol 2003;39:S206-11.
17. Marusawa H, Uemoto S, Hijikata M, et al. Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen. Hepatology 2000;31:488-95.